SI2185155T1 - Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors - Google Patents
Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors Download PDFInfo
- Publication number
- SI2185155T1 SI2185155T1 SI200831900T SI200831900T SI2185155T1 SI 2185155 T1 SI2185155 T1 SI 2185155T1 SI 200831900 T SI200831900 T SI 200831900T SI 200831900 T SI200831900 T SI 200831900T SI 2185155 T1 SI2185155 T1 SI 2185155T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ligands
- dopamine
- methods
- receptor ligands
- dopamine receptor
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract 7
- 102000015554 Dopamine receptor Human genes 0.000 title claims abstract 6
- 108050004812 Dopamine receptor Proteins 0.000 title claims abstract 6
- 238000000034 method Methods 0.000 title claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 208000024714 major depressive disease Diseases 0.000 claims abstract 2
- PZWXYRDNQYUIIU-UHFFFAOYSA-N 3-cyclohexyl-1,1-dimethylurea Chemical compound CN(C)C(=O)NC1CCCCC1 PZWXYRDNQYUIIU-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000025307 bipolar depression Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pregnancy & Childbirth (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95369407P | 2007-08-03 | 2007-08-03 | |
| EP08782602.0A EP2185155B1 (en) | 2007-08-03 | 2008-08-04 | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
| PCT/US2008/072066 WO2009020897A1 (en) | 2007-08-03 | 2008-08-04 | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2185155T1 true SI2185155T1 (en) | 2018-02-28 |
Family
ID=40338740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831900T SI2185155T1 (en) | 2007-08-03 | 2008-08-04 | Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20090036468A1 (enExample) |
| EP (1) | EP2185155B1 (enExample) |
| JP (1) | JP5460594B2 (enExample) |
| KR (1) | KR101612563B1 (enExample) |
| CN (1) | CN101815519B (enExample) |
| AU (1) | AU2008283989B2 (enExample) |
| CA (1) | CA2695519A1 (enExample) |
| CY (1) | CY1119828T1 (enExample) |
| DK (1) | DK2185155T3 (enExample) |
| EA (1) | EA018064B1 (enExample) |
| ES (1) | ES2653852T3 (enExample) |
| HR (1) | HRP20171908T1 (enExample) |
| HU (1) | HUE036004T2 (enExample) |
| LT (1) | LT2185155T (enExample) |
| MY (1) | MY157192A (enExample) |
| NO (1) | NO2185155T3 (enExample) |
| PL (1) | PL2185155T3 (enExample) |
| PT (1) | PT2185155T (enExample) |
| SI (1) | SI2185155T1 (enExample) |
| WO (1) | WO2009020897A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2730287C (en) | 2008-07-16 | 2017-02-07 | Forest Laboratories Holdings Limited | Pharmaceutical formulations containing dopamine receptor ligands |
| US20110117214A1 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| MX353209B (es) * | 2010-06-18 | 2018-01-08 | Altos Therapeutics Llc | Antagonistas d2, metodos de sintesis y metodos de uso. |
| US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| HUP1700253A1 (hu) * | 2017-06-13 | 2019-01-28 | Richter Gedeon Nyrt | Szilárd orális gyógyszerkészítmények |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| HU231500B1 (hu) * | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| JP2022529476A (ja) | 2019-04-17 | 2022-06-22 | コンパス パスファインダー リミテッド | 不安障害、頭痛障害、及び摂食障害をサイロシビンで治療するための方法 |
| GEAP202416526A (en) * | 2021-10-28 | 2024-09-25 | Richter Gedeon Nyrt | Treatment of major depressive disorder |
| JP2025500844A (ja) * | 2021-12-13 | 2025-01-15 | コンパス パスファインダー リミテッド | 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤 |
| JP2025509390A (ja) * | 2022-03-17 | 2025-04-11 | マピ ファーマ リミテッド | カリプラジン又はその塩を含むデポシステム |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| US6556540B1 (en) * | 1998-05-29 | 2003-04-29 | Paradyne Corporation | System and method for non-intrusive measurement of service quality in a communications network |
| DE19983836C1 (de) * | 1999-10-25 | 2003-10-23 | Lundbeck As Valby H | Verfahren zur Herstellung von Citalopram, 4-[1-(4- Fluorphenyl)-methanoyl]-benzonitril-Derivate und Verfahren zu deren Herstellung und deren Verwendung |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| UA82828C2 (en) * | 2001-05-01 | 2008-05-26 | Lundbeck & Co As H | The use of enantiomeric pure escitalopram for treatment of depression |
| AU2003235442A1 (en) * | 2002-04-12 | 2003-10-27 | Sepracor, Inc. | 3-aza- and 1,4-diaza-bicyclo(4.3.0)nonanes, and methods of use thereof |
| ES2282632T3 (es) * | 2002-06-20 | 2007-10-16 | H. Lundbeck A/S | Terapia de combinacion en la que se usa un inhibidor de la reabsorcion de serotonina. |
| HU227534B1 (en) * | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| KR20060072127A (ko) * | 2003-09-04 | 2006-06-27 | 하. 룬트벡 아크티에 셀스카브 | 세로토닌 재흡수 억제제 및 록사핀의 조합 |
| HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| HU230748B1 (hu) * | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
-
2008
- 2008-08-04 MY MYPI2010000523A patent/MY157192A/en unknown
- 2008-08-04 WO PCT/US2008/072066 patent/WO2009020897A1/en not_active Ceased
- 2008-08-04 ES ES08782602.0T patent/ES2653852T3/es active Active
- 2008-08-04 CA CA2695519A patent/CA2695519A1/en not_active Abandoned
- 2008-08-04 JP JP2010520238A patent/JP5460594B2/ja active Active
- 2008-08-04 KR KR1020107004638A patent/KR101612563B1/ko active Active
- 2008-08-04 PL PL08782602T patent/PL2185155T3/pl unknown
- 2008-08-04 CN CN2008801062563A patent/CN101815519B/zh active Active
- 2008-08-04 EP EP08782602.0A patent/EP2185155B1/en active Active
- 2008-08-04 DK DK08782602.0T patent/DK2185155T3/en active
- 2008-08-04 US US12/185,211 patent/US20090036468A1/en not_active Abandoned
- 2008-08-04 HR HRP20171908TT patent/HRP20171908T1/hr unknown
- 2008-08-04 AU AU2008283989A patent/AU2008283989B2/en active Active
- 2008-08-04 NO NO08782602A patent/NO2185155T3/no unknown
- 2008-08-04 SI SI200831900T patent/SI2185155T1/en unknown
- 2008-08-04 LT LTEP08782602.0T patent/LT2185155T/lt unknown
- 2008-08-04 EA EA201000280A patent/EA018064B1/ru unknown
- 2008-08-04 HU HUE08782602A patent/HUE036004T2/hu unknown
- 2008-08-04 PT PT87826020T patent/PT2185155T/pt unknown
-
2010
- 2010-09-27 US US12/890,752 patent/US20110015208A1/en not_active Abandoned
-
2011
- 2011-10-10 US US13/269,928 patent/US20120028991A1/en not_active Abandoned
-
2017
- 2017-12-07 CY CY20171101293T patent/CY1119828T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO2185155T3 (enExample) | 2018-03-03 |
| AU2008283989A1 (en) | 2009-02-12 |
| EA201000280A1 (ru) | 2010-08-30 |
| EA018064B1 (ru) | 2013-05-30 |
| JP5460594B2 (ja) | 2014-04-02 |
| MY157192A (en) | 2016-05-13 |
| CN101815519B (zh) | 2013-08-21 |
| LT2185155T (lt) | 2017-12-11 |
| CA2695519A1 (en) | 2009-02-12 |
| CN101815519A (zh) | 2010-08-25 |
| EP2185155A4 (en) | 2012-04-25 |
| EP2185155B1 (en) | 2017-10-04 |
| PL2185155T3 (pl) | 2018-03-30 |
| DK2185155T3 (en) | 2018-01-02 |
| ES2653852T3 (es) | 2018-02-09 |
| CY1119828T1 (el) | 2018-06-27 |
| US20090036468A1 (en) | 2009-02-05 |
| HRP20171908T1 (hr) | 2018-01-26 |
| PT2185155T (pt) | 2018-01-04 |
| KR101612563B1 (ko) | 2016-04-14 |
| US20110015208A1 (en) | 2011-01-20 |
| JP2010535790A (ja) | 2010-11-25 |
| US20120028991A1 (en) | 2012-02-02 |
| HUE036004T2 (hu) | 2018-06-28 |
| KR20100059830A (ko) | 2010-06-04 |
| EP2185155A1 (en) | 2010-05-19 |
| HK1144784A1 (en) | 2011-03-11 |
| AU2008283989B2 (en) | 2013-12-05 |
| WO2009020897A1 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2185155T1 (en) | Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors | |
| ZA200700765B (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol | |
| BRPI0412351A (pt) | derivados e piridilamino-pirimidina como inibidores de proteìna quinase | |
| JP2011148799A5 (enExample) | ||
| DK2182949T3 (da) | (2S,3R)-N-(2-((3-Pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamid, nye saltformer samt fremgangsmåder til deres anvendelse | |
| ATE498620T1 (de) | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| NO20080670L (no) | Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister | |
| CY1112727T1 (el) | Παραγωγα κυκλοβουτυλ αμινης βενζοθειαζολης και η χρηση αυτων ως προσδετες των υποδοχεων ισταμινης-3 | |
| UA100877C2 (ru) | Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3) | |
| MY151211A (en) | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| UA98772C2 (ru) | Производные циклопропиламина как модуляторы н3-гистаминового рецептора | |
| WO2007032028A8 (en) | Thiazolinones and oxazolinones and their use as ptp1b inhibitors | |
| WO2007121389A3 (en) | 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| NO20084674L (no) | 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser | |
| BRPI0518949A2 (pt) | composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica | |
| TW200604165A (en) | Novel benzyl(idene)-lactam derivatives | |
| UA97648C2 (ru) | N-(2-гидроксиэтил)-n-метил-4-(хинолин-8-ил(1-(тиазол-4-илметил)пиперидин-4-илиден)метил)бензамид, способ его получения (варианты), фармацевтическая композиция и его применение для подавления боли или для лечения депрессии, тревожности или болезни паркинсона | |
| BRPI0519709A2 (pt) | derivados de tetralina e indano e usos dos mesmos como antagonistas de 5-ht | |
| MX2007003471A (es) | Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona. | |
| CY1109018T1 (el) | Φαρμακευτικη συνθεση που περιεχει ενα αλας μιρταζαπινης | |
| EA201000613A1 (ru) | Тризамещенные пиперидины |